Eisai enters into licensing agreement with medac concerning Methotrexate Subcutaneous Injection in Japan

Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan.

Original source: https://health.economictimes.indiatimes.com/news/pharma/eisai-enters-into-licensing-agreement-with-medac-concerning-methotrexate-subcutaneous-injection-in-japan/69263812?utm_source=RSS&utm_medium=ETRSS

Related Posts